LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Geron Corp

Closed

SectorHealthcare

1.2 0.84

Overview

Share price change

24h

Current

Min

1.18

Max

1.21

Key metrics

By Trading Economics

Income

5.5M

-20M

Sales

-7.9M

40M

EPS

-0.03

Profit margin

-50.085

Employees

229

EBITDA

-375K

-17M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+204.96% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-871M

815M

Previous open

0.36

Previous close

1.2

News Sentiment

By Acuity

78%

22%

362 / 382 Healthcare

Geron Corp Chart

Past performance is not a reliable indicator of future results.

Related News

7 Jun 2024, 10:19 UTC

Major Market Movers

Geron Shares Rise Premarket on FDA Nod for Rytelo

Peer Comparison

Price change

Geron Corp Forecast

Price Target

By TipRanks

204.96% upside

12 Months Forecast

Average 3.69 USD  204.96%

High 6 USD

Low 1.5 USD

Based on 9 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Sentiment

By Acuity

362 / 382 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.